Food and Drug Administration
Briefing Information
The committee will discuss the Implications of recently available data related
to the safety of long-acting beta-agonist bronchodilators.
Disclaimer
The
statements contained in this document(s) are those of the product's sponsor,
not FDA,
and FDA does not necessarily agree with the sponsor's statements..
Novartis Pharmaceuticals
Corporation
Novartis Appendix 1
Novartis Appendix 2
FDA
Disclaimer
Portions of this document have
been determined to be exempt from disclosure under the Freedom of Information
Act (the FOIA) (5 U.S.C. §552).
These redacted portions will appear as
white space on the screen or on the printed page.